Search clinical trials for: CVD 1208S, a Shigella flexneri 2a live, oral vaccine

Total 18 results

University of Maryland, Baltimore
PATH

Completed

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP

Shigella

United States
University of Maryland, Baltimore
PATH

Terminated

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa

Shigella

United States
University of Maryland, Baltimore
PATH

Terminated

Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb

Shigella

United States
U.S. Army Medical Research and Development Command
U.S. Army Office of the Surgeon General

Completed

Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection

Shigellosis

United States
PATH

Withdrawn

Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults

Shigella Sonnei Dysenteries

United States
University of Maryland, Baltimore

Completed

Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine

Shigella

United States
Eunice Kennedy Shriver National Institute of Child...
The Chaim Sheba Medical Center; Schneider Children's Medical Center, Israel

Completed

Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel

Shigellosis

Israel
University of Maryland, Baltimore
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A Infection

Salmonella

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America

Dengue | Dengue Hemorrhagic Fever

Brazil
Sanofi Pasteur, a Sanofi Company

Completed

Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers

Yellow Fever | Dengue | Dengue Hemorrhagic Fever

Peru, Colombia
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort (SLVP033)

Hepatitis A | Influenza | Healthy Adults | Typhoid

United States
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (MEQ00064)

Healthy Volunteers | Meningococcal Immunisation

South Africa, India
Sanofi

Completed

A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines

Dengue Fever | Dengue Hemorrhagic Fever

Philippines
Limited Liability Company Pharm Aid

Completed

Reactogenicity, Safety and Immunological Efficacy of the Live, Pentavalent Rotavirus Vaccine in Childhood Immunization

Rotavirus Infection

Russian Federation
Limited Liability Company Pharm Aid

Completed

Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.

Rotavirus Infections | Rotavirus Vaccines

Russian Federation
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

Meningitis, Meningococcal

United States, Argentina, Colombia
Julio Ramirez
University of Louisville

Terminated

Patients Response to Early Switch To Oral:Osteomyelitis Study (PRESTO:Osteo)

Osteomyelitis

United States

3

Subscribe